Linezolid — a generic form of Pharmacia & Upjohn‘s brand name Zyvox injection — is intended to treat infections caused by susceptible Gram-positive bacteria.
The newly approved drug has an estimated market value of $87 million for the 12 months ending in June 2016.
India-based Aurobindo Pharma expects to launch the product by the end of the second quarter. The linezolid injection marks the drugmaker‘s 275th FDA approval.
More articles on the drug market:
AbbVie sues Amgen for patent infringement on Humira: 5 things to know
Bristol-Myers stock dips 18% following failed trial
Drug company drives $48k brain-eating amoeba treatment to SC hospital
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
